Potential mechanisms of atypical antipsychotic-induced hypertriglyceridemia

Psychopharmacology

Volumn 229, Issue 1, 2013, Pages 1-7

  Yan, Hu ^a   Chen, Jin Dong ^a   Zheng, Xiao Yan ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Adipose tissue; Atypical antipsychotics; Hypertriglyceridemia; Lipolysis; SREBP

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A5; APOLIPOPROTEIN C3; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; ICOSAPENTAENOIC ACID; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; OLANZAPINE; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TOPIRAMATE; VERY LOW DENSITY LIPOPROTEIN;

ABDOMINAL OBESITY; APOA5 GENE; APOC3 GENE; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME REPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; HIGH RISK POPULATION; HUMAN; HYDROLYSIS; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPID METABOLISM; LIPOGENESIS; LIPOLYSIS; MENTAL DISEASE; MOLECULAR PATHOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LIPID INTERACTION; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TRIGLYCERIDE PRODUCTION; TRIGLYCERIDE SECRETION; UPREGULATION; WEIGHT GAIN; WEIGHT REDUCTION;

ANIMALS; ANTIPSYCHOTIC AGENTS; HUMANS; HYPERTRIGLYCERIDEMIA; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 84879620287     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-013-3193-7     Document Type: Review

References (73)

1. Adachi H, Yanai H, Hirowatari Y (2012) The underlying mechanisms for olanzapine-induced hypertriglyceridemia. J Clin Med Res 4:206-208
2. Adiels M, Boren J, Caslake MJ, Stewart P, Soro A, Westerbacka J, Wennberg B, Olofsson SO, Packard C, Taskinen MR (2005) Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia. Arterioscler Thromb Vasc Biol 25:1697-1703
3. Amemiya-Kudo M, Shimano H, Hasty AH, Yahagi N, Yoshikawa T, Matsuzaka T, Okazaki H, Tamura Y, Iizuka Y, Ohashi K, Osuga J, Harada K, Gotoda T, Sato R, Kimura S, Ishibashi S, Yamada N (2002) Transcriptional activities of nuclear SREBP-1a, -1c, and -2 to different target promoters of lipogenic and cholesterogenic genes. J Lipid Res 43:1220-1235
4. Arulmozhi DK, Dwyer DS, Bodhankar SL (2006) Antipsychotic induced metabolic abnormalities: an interaction study with various PPAR modulators in mice. Life Sci 79:1865-1872
5. Atmaca M, Kuloglu M, Tezcan E, Ustundag B (2003) Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 64:598-604
6. Baptista T, Uzcategui E, Rangel N, El Fakih Y, Galeazzi T, Beaulieu S, de Baptista EA (2008) Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study. Psychiatry Res 159:250-253
7. Ben-Menachem E, Axelsen M, Johanson EH, Stagge A, Smith U (2003) Predictors of weight loss in adults with topiramate-treated epilepsy. Obes Res 11:556-562
8. Birkenaes AB, Birkeland KI, Engh JA, Faerden A, Jonsdottir H, Ringen PA, Friis S, Opjordsmoen S, Andreassen OA (2008) Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol 28:132-137
9. Bishop JR, Stanford KI, Esko JD (2008) Heparan sulfate proteoglycans and triglyceride-rich lipoprotein metabolism. Curr Opin Lipidol 19:307-313
10. Boyda HN, Tse L, Procyshyn RM, Honer WG, Barr AM (2010) Preclinical models of antipsychotic drug-induced metabolic side effects. Trends Pharmacol Sci 31:484-497
11. Brown MS, Goldstein JL (2008) Selective versus total insulin resistance: a pathogenic paradox. Cell Metab 7:95-96
12. Buckley PF (2001) Broad therapeutic uses of atypical antipsychotic medications. Biol Psychiatry 50:912-924
13. Chao PM, Kuo YH, Lin YS, Chen CH, Chen SW (2010) The metabolic benefits of Polygonum hypoleucum Ohwi in HepG2 cells and Wistar rats under lipogenic stress. J Agric Food Chem 58:5174-5180
14. Chen CH, Chiu CC, Huang MC, Wu TH, Liu HC, Lu ML (2008) Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine. Prog Neuropsychopharmacol Biol Psychiatry 32:925-931
15. Coccurello R, Moles A (2010) Potential mechanisms of atypical antipsychotic-induced metabolic derangement: clues for understanding obesity and novel drug design. Pharmacol Ther 127:210-251
16. De Hert M, Kalnicka D, van Winkel R, Wampers M, Hanssens L, Van Eyck D, Scheen A, Peuskens J (2006) Treatment with rosuvastatin for severe dyslipidemia in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 67:1889-1896
17. de Leon J, Correa JC, Ruano G, Windemuth A, Arranz MJ, Diaz FJ (2008) Exploring genetic variations that may be associated with the direct effects of some antipsychotics on lipid levels. Schizophr Res 98:40-46
18. de Leon J, Diaz FJ (2007) Planning for the optimal design of studies to personalize antipsychotic prescriptions in the post-CATIE era: the clinical and pharmacoepidemiological data suggest that pursuing the pharmacogenetics of metabolic syndrome complications (hypertension, diabetes mellitus and hyperlipidemia) may be a reasonable strategy. Schizophr Res 96:185-197
19. Diaz FJ, Meary A, Arranz MJ, Ruano G, Windemuth A, de Leon J (2009) Acetyl-coenzyme A carboxylase alpha gene variations may be associated with the direct effects of some antipsychotics on triglyceride levels. Schizophr Res 115:136-140
20. Eckel RH (1989) Lipoprotein lipase. A multifunctional enzyme relevant to common metabolic diseases. N Engl J Med 320:1060-1068
21. Eder U, Mangweth B, Ebenbichler C, Weiss E, Hofer A, Hummer M, Kemmler G, Lechleitner M, Fleischhacker WW (2001) Association of olanzapine-induced weight gain with an increase in body fat. Am J Psychiatry 158:1719-1722
22. Ferno J, Raeder MB, Vik-Mo AO, Skrede S, Glambek M, Tronstad KJ, Breilid H, Lovlie R, Berge RK, Stansberg C, Steen VM (2005) Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics J 5:298-304
23. Fukuen S, Iwaki M, Yasui A, Makishima M, Matsuda M, Shimomura I (2005) Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity. J Biol Chem 280:23653-23659
24. Harwood HJ Jr (2005) Treating the metabolic syndrome: acetyl-CoA carboxylase inhibition. Expert Opin Ther Targets 9:267-281
25. Hemmrich K, Gummersbach C, Pallua N, Luckhaus C, Fehsel K (2006) Clozapine enhances differentiation of adipocyte progenitor cells. Mol Psychiatry 11:980-981
26. Hong CJ, Chen TT, Bai YM, Liou YJ, Tsai SJ (2011) Impact of apolipoprotein A5 (APOA5) polymorphisms on serum triglyceride levels in schizophrenic patients under long-term atypical antipsychotic treatment. World J Biol Psychiatry 13:22-29
27. Horton JD, Goldstein JL, Brown MS (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109:1125-1131
28. Joy CB, Mumby-Croft R, Joy LA (2006) Polyunsaturated fatty acid supplementation for schizophrenia. Cochrane Database Syst Rev: CD001257
29. Karasawa T, Takahashi A, Saito R, Sekiya M, Igarashi M, Iwasaki H, Miyahara S, Koyasu S, Nakagawa Y, Ishii K, Matsuzaka T, Kobayashi K, Yahagi N, Takekoshi K, Sone H, Yatoh S, Suzuki H, Yamada N, Shimano H (2011) Sterol regulatory element-binding protein-1 determines plasma remnant lipoproteins and accelerates atherosclerosis in low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 31:1788-1795
30. Koro CE, Fedder DO, L'Italien GJ, Weiss S, Magder LS, Kreyenbuhl J, Revicki D, Buchanan RW (2002) An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 59:1021-1026
31. Landry P, Dimitri E, Tessier S, Legare N (2008) Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study. J Clin Psychopharmacol 28:348-349
32. Lauressergues E, Staels B, Valeille K, Majd Z, Hum DW, Duriez P, Cussac D (2010) Antipsychotic drug action on SREBPs-related lipogenesis and cholesterogenesis in primary rat hepatocytes. Naunyn Schmiedebergs Arch Pharmacol 381:427-439
33. Markham-Abedi C, de Leon J (2006) Hypertriglyceridemia associated with direct effects of olanzapine rather than with weight gain: a case report. J Clin Psychiatry 67:1473-1474
34. Mauriege P, Marette A, Atgie C, Bouchard C, Theriault G, Bukowiecki LK, Marceau P, Biron S, Nadeau A, Despres JP (1995) Regional variation in adipose tissue metabolism of severely obese premenopausal women. J Lipid Res 36:672-684
35. Merkel M, Loeffler B, Kluger M, Fabig N, Geppert G, Pennacchio LA, Laatsch A, Heeren J (2005) Apolipoprotein AV accelerates plasma hydrolysis of triglyceride-rich lipoproteins by interaction with proteoglycan-bound lipoprotein lipase. J Biol Chem 280:21553-21560
36. Meyer JM (2001a) Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry 62(Suppl 27):27-34, discussion 40-41
37. Meyer JM (2001b) Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 21:369-374
38. Meyer JM (2002) A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 63:425-433
39. Meyer JM, Koro CE (2004) The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 70:1-17
40. Minet-Ringuet J, Even PC, Valet P, Carpene C, Visentin V, Prevot D, Daviaud D, Quignard-Boulange A, Tome D, de Beaurepaire R (2007) Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment. Mol Psychiatry 12:562-571
41. Mitrou P, Boutati E, Lambadiari V, Maratou E, Komesidou V, Papakonstantinou A, Sidossis L, Tountas N, Katsilambros N, Economopoulos T, Raptis SA, Dimitriadis G (2010) Rates of lipid fluxes in adipose tissue in vivo after a mixed meal in morbid obesity. Int J Obes (Lond) 34:770-774
42. Moon YA, Liang G, Xie X, Frank-Kamenetsky M, Fitzgerald K, Koteliansky V, Brown MS, Goldstein JL, Horton JD (2012) The Scap/SREBP pathway is essential for developing diabetic fatty liver and carbohydrate-induced hypertriglyceridemia in animals. Cell Metab 15:240-246
43. Nagamine T (2008) Olanzapine-induced elevation of serum triglyceride levels in a normal weight patient with schizophrenia. Intern Med 47:181-182
44. Narula PK, Rehan HS, Unni KE, Gupta N (2010) Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial. Schizophr Res 118:218-223
45. Newall H, Myles N, Ward PB, Samaras K, Shiers D, Curtis J (2012) Efficacy of metformin for prevention of weight gain in psychiatric populations: a review. Int Clin Psychopharmacol 27:69-75
46. Oh KJ, Park J, Lee SY, Hwang I, Kim JB, Park TS, Lee HJ, Koo SH (2011) Atypical antipsychotic drugs perturb AMPK-dependent regulation of hepatic lipid metabolism. Am J Physiol Endocrinol Metab 300:E624-E632
47. Ojala K, Repo-Tiihonen E, Tiihonen J, Niskanen L (2008) Statins are effective in treating dyslipidemia among psychiatric patients using second-generation antipsychotic agents. J Psychopharmacol 22:33-38
48. Olfson M, Marcus SC, Corey-Lisle P, Tuomari AV, Hines P, L'Italien GJ (2006) Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry 163:1821-1825
49. Panarotto D, Remillard P, Bouffard L, Maheux P (2002) Insulin resistance affects the regulation of lipoprotein lipase in the postprandial period and in an adipose tissue-specific manner. Eur J Clin Invest 32:84-92
50. Pavan C, Vindigni V, Michelotto L, Rimessi A, Abatangelo G, Cortivo R, Pinton P, Zavan B (2010) Weight gain related to treatment with atypical antipsychotics is due to activation of PKC-beta. Pharmacogenomics J 10:408-417
51. Peet M, Horrobin DF (2002) A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 36:7-18
52. Perez-Iglesias R, Mata I, Pelayo-Teran JM, Amado JA, Garcia-Unzueta MT, Berja A, Martinez-Garcia O, Vazquez-Barquero JL, Crespo-Facorro B (2009) Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naive population. Schizophr Res 107:115-121
53. Potts JL, Coppack SW, Fisher RM, Humphreys SM, Gibbons GF, Frayn KN (1995) Impaired postprandial clearance of triacylglycerol-rich lipoproteins in adipose tissue in obese subjects. Am J Physiol 268:E588-E594
54. Raeder MB, Ferno J, Vik-Mo AO, Steen VM (2006) SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects? Mol Cell Biochem 289:167-173
55. Reaven GM, Lieberman JA, Sethuraman G, Kraemer H, Davis JM, Blasey C, Tsuang MT, Schatzberg AF (2009) In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment. J Psychiatr Res 43:997-1002
56. Shimomura I, Matsuda M, Hammer RE, Bashmakov Y, Brown MS, Goldstein JL (2000) Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell 6:77-86
57. Shin L, Bregman H, Breeze JL, Noyes N, Frazier JA (2009) Metformin for weight control in pediatric patients on atypical antipsychotic medication. J Child Adolesc Psychopharmacol 19:275-279
58. Sinn N, Milte C, Howe PR (2010) Oiling the brain: a review of randomized controlled trials of omega-3 fatty acids in psychopathology across the lifespan. Nutrients 2:128-170
59. Skrede S, Ferno J, Vazquez MJ, Fjaer S, Pavlin T, Lunder N, Vidal-Puig A, Dieguez C, Berge RK, Lopez M, Steen VM (2012) Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats. Int J Neuropsychopharmacol 15:163-179
60. Smith RC, Segman RH, Golcer-Dubner T, Pavlov V, Lerer B (2008) Allelic variation in ApoC3, ApoA5 and LPL genes and first and second generation antipsychotic effects on serum lipids in patients with schizophrenia. Pharmacogenomics J 8:228-236
61. Sparks JD, Sparks CE, Adeli K (2012) Selective hepatic insulin resistance, VLDL overproduction, and hypertriglyceridemia. Arterioscler Thromb Vasc Biol 32:2104-2112
62. Subramanian S, Chait A (2012) Hypertriglyceridemia secondary to obesity and diabetes. Biochim Biophys Acta 1821:819-825
63. van de Woestijne AP, Monajemi H, Kalkhoven E, Visseren FL (2011) Adipose tissue dysfunction and hypertriglyceridemia: mechanisms and management. Obes Rev 12:829-840
64. Vestri HS, Maianu L, Moellering DR, Garvey WT (2007) Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis. Neuropsychopharmacology 32:765-772
65. Victoriano M, de Beaurepaire R, Naour N, Guerre-Millo M, Quignard-Boulange A, Huneau JF, Mathe V, Tome D, Hermier D (2010) Olanzapine-induced accumulation of adipose tissue is associated with an inflammatory state. Brain Res 1350:167-175
66. Vik-Mo AO, Birkenaes AB, Ferno J, Jonsdottir H, Andreassen OA, Steen VM (2008) Increased expression of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients. Int J Neuropsychopharmacol 11:679-684
67. Vincenzi B, Borba CP, Gray DA, Copeland PM, Wang X, Fan X, Aragam GG, Henderson DC (2013) An exploratory study examining lipid-lowering medications in reducing fasting serum lipids in schizophrenia patients treated with atypical antipsychotics. Ann Clin Psychiatry 25:141-148
68. Wang CS, McConathy WJ, Kloer HU, Alaupovic P (1985) Modulation of lipoprotein lipase activity by apolipoproteins. Effect of apolipoprotein C-III J Clin Invest 75:384-390
69. Weiden PJ, Daniel DG, Simpson G, Romano SJ (2003) Improvement in indices of health status in outpatients with schizophrenia switched to ziprasidone. J Clin Psychopharmacol 23:595-600
70. Wetterling T, Schneider B, Weber B (2007) Dyslipidemia and schizophrenia. Psychiatr Prax 34:223-229
71. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC (2002) The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 63:856-865
72. Yang LH, Chen TM, Yu ST, Chen YH (2007) Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells. Pharmacol Res 56:202-208
73. Yang Z, Yin JY, Gong ZC, Huang Q, Chen H, Zhang W, Zhou HH, Liu ZQ (2009) Evidence for an effect of clozapine on the regulation of fat-cell derived factors. Clin Chim Acta 408:98-104